Stockreport

REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

Tyme Technologies, Inc.  (TYME) 
Last tyme technologies, inc. earnings: 2/5 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: tymeinc.com/investors
PDF In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019 Efficacy indicators showed strong correlation with [Read more]